Management

Peter Zerhouni

Chief Executive Officer (CEO)

Born: 1972.

Position: Zerhouni is the CEO of InDex Pharmaceuticals Holding AB since 2016 and of InDex Pharmaceuticals AB and InDex Diagnostics AB since 2015. Zerhouni is board member of InDex Pharmaceuticals AB and InDex Diagnostics AB since 2017.

Other current assignments: Zerhouni is auditor in Reimersholmes Kooperativa Daghem ekonomiska förening.

Prior assignments (last five years): Zerhouni was CEO of Diamyd Medical Group and Diamyd Medical AB until 2015, Mertiva AB and Mertiva Diagnostics AB until 2013 as well as board member of Cellaviva AB until 2015.

Other relevant experience: Zerhouni has extensive experience in developing life science companies from both a scientific and commercial perspective. Peter joined InDex from the listed company Diamyd Medical AB where he was CEO since 2011 and where he also has been head of business development. He was a driving force behind one of the largest biotech out-licensing deals in Sweden in 2010. Zerhouni has previously held various positions at ING Bank in Brussels and Amsterdam. He holds a Master of Science degree in Biology as well as a Business of Science degree in Business Administration from Lund University (part of the course work was completed at University of California at Berkely).

Shareholding in InDex: Direct holding of 34 000 shares and 800 000 warrants 2016-2019.

Johan Giléus

Chief Financial Officer (CFO)

Born: 1965.

Position: Giléus is CFO of InDex since May 2017. Giléus is board member of InDex Pharmaceuticals AB and InDex Diagnostics AB since 2017.

Other current assignments: Giléus is CEO of Giléus Consulting AB and a member of the board and chairman of the audit committee of Haldex AB.

Prior assignments (last five years): Giléus was until May 2015 partner at Deloitte AB with a focus on M&A and stock market issues. Giléus was also on the board of Deloitte AB up until 2014.

Other relevant experience: Giléus is also engaged as an independent financial advisor with M&A, external financial reporting and other stock market issues. He has broad experience from sectors like Life Science, Energy, Services and Manufacturing. During the last 25 years Giléus has worked with Swedish and international strategic and financial clients in acquisitions and divestments. He has also been involved in some 75 IPOs. Giléus has studied business administration at Stockholm University.

Shareholding in InDex: Direct holding of 20 000 shares and 175 000 warrants 2016-2019.

Dr. Thomas Knittel

Chief Medical Officer (CMO)

Born: 1962.

Position: Knittel is CMO of InDex since 2012.

Other current assignments: Not applicable

Prior assignments (last five years): Knittel was CEO of Gastrogenics UG unti 2015, consultant for Medoderm GmbH until 2013, general manager of Harlan Laboratories Ltd. until 2011 and Business Unit Director and Director of Sales and Marketing at Novo Nordisk Pharma GmbH until 2010.

Other relevant experience: Knittel has over 15 years of clinical experience within medical gastroenterology as well as 13 years of experience in medical affairs and marketing management. Before joining InDex Pharmaceuticals, he held positions as Business Unit Director and Director of Sales and Marketing at Novo Nordisk A/S for central Europe, as General Manager Pharmaceuticals at Harlan Laboratories Ltd, and as Vice President Corporate and Medical Affairs at Develogen AG. He has a Medical degree from the University of Mains with a specialist training in internal medicine and gastroenterology. He is an Associate Professor in Internal Medicine and Gastroenterology at the University Clinic Goettingen. In addition, he has an MBA from Kellogg School of Management/WHU.

Shareholding in InDex: Direct holding of 15 000 shares and 175 000 warrants 2016-2019.

Pernilla Sandwall

Chief Operating Officer (COO)

Born: 1963.

Position: Sandwall is COO of InDex since 2012.

Other current assignments: Sandwall is a board member of Innovativa Mindre Life science företag (IML, which is a part of the trade association Läkemedelsindustriföreningen).

Prior assignments (last five years): Sandwall was until 2015 member of the expert working group for clinical trials and regulatory affairs of SwedenBio. Sandwall was until 2018 board member of Pharmacists without borders.

Other relevant experience: Sandwall has worked at Merck & Co. Inc./MSD for more than 20 years, both in the Swedish subsidiary and the headquarters in US, with the clinical operations organization. She has experience in the field as CRA and project manager, as well as strategically as Clinical Research Manager. Her focus over the last years has been global patient recruitment, site selection strategies and execution. She also has experience in change management and Lean Six Sigma methodology. She holds a Master of Science in Pharmacy from Uppsala University.

Shareholding in InDex: Direct holding of 25 000 shares and 350 000 warrants 2016-2019.